'/%3e%3c/g%3e%3c/svg%3e)
Searches about switching between Wegovy and Mounjaro are common when results plateau, side effects become troublesome, or treatment goals change. A switch can be medically reasonable, but it should always be planned together with a clinician.
When is a switch considered?
Clinicians usually think about switching when appetite control is still poor, weight loss has stalled, or gastrointestinal side effects make the current option hard to continue.
What does the research say?
Head-to-head data suggest tirzepatide often leads to greater average weight loss than semaglutide, but individual response still varies and expectations have to stay realistic.
How is the switch done in practice?
The old medicine is usually stopped and the new one is started from a low dose with a fresh escalation plan, not by jumping directly to a high dose.
What should you expect after switching?
A new adjustment period is common, including renewed dose titration, possible nausea or constipation, and gradual evaluation of hunger, adherence and weight trend.
